Pre-operative dysglycemia is associated with decreased survival in patients with pancreatic neuroendocrine neoplasms

Sandini, Marta; Strobel, Oliver; Hank, Thomas; Lewosinska, Magdalena; Nießen, Anna; Hackert, Thilo; Büchler, Markus W.; Schimmack, Simon

doi:10.1016/j.surg.2019.11.007

Cited by 18 publications

(15 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A few studies have shown the role of DM in the biological behavior of PNENs (12). The risks of nerve invasion and distant metastasis were higher in PNEN patients with diabetes or dysglycemia than those without diabetes (12,13). Our study found that nerve invasion was associated with impaired fasting glucose and DM, which was consistent with previous studies.…”

Section: Discussionsupporting

confidence: 91%

“…( 12 ) showed that the risk of DM in PNEN patients with distant metastases was higher than without it. A similar association was also observed in PNEN patients with dysglycemia (blood glucose >140 mg/dl) ( 13 ). Previous data also indicated that PNENs’ grade was associated with DM ( 12 ).…”

Section: Discussionsupporting

confidence: 72%

“…DM has become a challenge for public health in China (11). Few studies have shown the prevalence of DM or impaired fasting glucose in PNENs (5,12,13). Ben et al (5) indicated that the prevalence of T2DM was 16.9% in a Chinese PNEN population.…”

Section: Introductionmentioning

confidence: 99%

“…Insulinoma was included in those two Chinese studies. A recent study showed that 28.3% of PNENs (insulinoma or glucagonoma was excluded) patients had DM or dysglycemia (blood glucose >140 mg/dl) in a German population ( 13 ). Insulinoma can decrease glucose levels by excessively secreting insulin and cause hypoglycemia.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Diabetes in Patients With Pancreatic Neuroendocrine Neoplasms

et al. 2020

View full text Add to dashboard Cite

ObjectiveDiabetes mellitus (DM) is probably a risk factor for pancreatic neuroendocrine neoplasms (PNENs). However, the prevalence of DM in PNEN patients remains inconclusive. In the present study we observed the prevalence of DM and possible risk factors in PNEN patients.MethodsAfter excluding those with insulinoma, a total of 197 patients with PNENs were included. The demographic data, pathological characteristics, and data of blood biochemical tests were recorded. DM was considered if there was evidence of a fasting plasma glucose level of ≥7.0 mmol/L or a 2-h plasma glucose level of ≥11.1 mmol/L, or a history of DM at the time of PNEN diagnosis. Impaired fasting glucose was considered if fasting plasma glucose level was between 6.1 and 7.0 mmol/L.ResultsThe prevalence of DM, new-onset DM, and impaired fasting glucose were 17.26, 9.14, and 7.1%, respectively. The prevalence of DM was 26.0% in patients ≥60 years old (19/73) and 12.1% in patients <60 years old. Multivariable logistic regression analysis demonstrated that age, tumor size, and nerve invasion were independent risk factors for DM and impaired fasting glucose + DM (p < 0.05). Age, organs and nerve invasion were independent risk factors for impaired fasting glucose. Low high-density lipoprotein (HDL) was also a risk factor for incident of DM (OR = 0.15, 95%CI: 0.03–0.66). G2/G3 was an independent risk factor for DM in women.ConclusionOur data shows that the prevalence of DM is 17.26% in patients with PNENs and is 26.0% in patients ≥60 years of age after excluding insulinoma. Age, nerve invasion, tumor size, and HDL are risk factors for DM in PNEN patients.

show abstract

Section: Discussionsupporting

confidence: 91%

Section: Discussionsupporting

confidence: 72%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Diabetes in Patients With Pancreatic Neuroendocrine Neoplasms

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Pan-NENs are a heterogeneous disease with different prognoses in different subgroups. 4,5 In addition to the existing tumor-node-metastasis (TNM) staging system, 6 tumor grade, 7 and differentiation status, 8 there are a number of emerging markers for predicting the prognosis of patients with Pan-NENs, including the blood glucose level, 9 peripheral blood neutrophil/lymphocyte ratio 10 and some other peripheral blood test markers. However, no studies have explored the prognostic value of the fibrinogen/albumin ratio (FAR) in Pan-NENs.…”

Section: Introductionmentioning

confidence: 99%